Formulation Development
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia will use proceeds from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases….
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study with…
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy & Related Conditions
Beacon Biosignals recently announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s neurophysiological platform to develop a better…
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Valneva SE recently reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day…
Data From First Human Study Demonstrate Excellent Performance of Zerion Pharma’s Dispersome Technology
Zerion Pharma A/S recently announced positive results from the first human clinical study of a Dispersome formulation of the drug Ivacaftor, a pharmaceutical used to…
Genespire Presents Positive Preclinical Proof of Concept Data
Genespire recently presented positive preclinical data at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) currently taking place in…
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 & Establishes Clinical Advisory Board
Mediar Therapeutics, Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced that, following FDA clearance of its investigational…
Arecor & Medtronic Diabetes Establish Collaboration to Develop Novel Thermostable Insulin for Implantable Pump Delivery
Medtronic to fund Arecor’s development of Arestat-enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination….
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
Bluejay Therapeutics recently announced the successful closure of a $182 million Series C financing round. This capital infusion will accelerate the clinical development of BJT-778,…
Attovia Therapeutics Raises $105 Million in Financing
Attovia Therapeutics recently announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the company since its launch…
Akoya Biosciences & NeraCare Enter Exclusive Agreement to Enable Personalized Therapy Selection for Early Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will…
Curia & Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
Curia and Carterra Inc. recently announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott….
Siren Biotechnology & Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology and Catalent Inc. recently entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene….
ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering First-in-Class Antiviral Innate Immunomodulator
ENA Respiratory recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 18/112091 titled “Novel molecules” covering claims for….
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR Therapeutics NV recently announced new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical proof of concept data for…
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
Therini Bio, Inc. recently announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases. The data…
FDA Grants Orphan Drug Designation to Biompharma’s Microbiome-Modifying Biologic
BIOM Pharmaceutical Corporation recently announced Bi104, its innovative drug product, has been granted orphan-drug designation by the US FDA for the treatment of Angelman syndrome…
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001), the company's lead clinical development program, for…
Derm-Biome Pharmaceuticals & TransBIOtech Awarded $450,000 Applied Research & Development Grant
Derm-Biome Pharmaceuticals, Inc. recently announced that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and…
WHITEPAPER - A Holistic Approach to Getting the First Batch Right
Mark Rauckhorst, director of supply chain and project management at leading, global contract development and manufacturing organization (CDMO) Vetter, will share his expert insights on how an outsource….
